In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy

BACKGROUND: CMP-001 is a novel Toll-like receptor-9 agonist that consists of an unmethylated CpG-A motif-rich G10 oligodeoxynucleotide (ODN) encapsulated in virus-like particles. In situ vaccination of CMP-001 is believed to activate local tumor-associated plasmacytoid dendritic cells (pDCs) leading...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yinwen, Lemke-Miltner, Caitlin D, Wongpattaraworakul, Wattawan, Wang, Zhaoming, Chan, Carlos H F, Salem, Aliasger K, Weiner, George J, Simons, Andrean L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566437/
https://www.ncbi.nlm.nih.gov/pubmed/33060147
http://dx.doi.org/10.1136/jitc-2020-000940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566437/
https://www.ncbi.nlm.nih.gov/pubmed/33060147
http://dx.doi.org/10.1136/jitc-2020-000940

Ejemplares similares